Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the vali...
Gespeichert in:
| Veröffentlicht in: | PloS one 2015-07, Vol.10 (7), p.e0133488-e0133488 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0133488 |
|---|---|
| container_issue | 7 |
| container_start_page | e0133488 |
| container_title | PloS one |
| container_volume | 10 |
| creator | Vincenzi, Bruno Di Maio, Massimo Silletta, Marianna D'Onofrio, Loretta Spoto, Chiara Piccirillo, Maria Carmela Daniele, Gennaro Comito, Francesca Maci, Eliana Bronte, Giuseppe Russo, Antonio Santini, Daniele Perrone, Francesco Tonini, Giuseppe |
| description | The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking.
To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival.
A comprehensive search of the literature was performed in electronic databases EMBASE, MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June 10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Loco-regional procedures included transarterial embolization (TAE), transarterial chemoembolization (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST was assessed using the k coefficient. For each criteria, overall survival was described in responders vs. non-responders patients, considering all target lesions response.
Among 18 initially found publications, 7 reports including 1357 patients were considered eligible. All studies were published as full-text articles. Proportion of responders according to mRECIST and EASL criteria was 62.4% and 61.3%, respectively. In the pooled population, 1286 agreements were observed between the two methods (kappa statistics 0.928, 95% confidence interval 0.912-0.944). HR for overall survival (responders versus non responders) according to mRECIST and EASL was 0.39 (95% confidence interval 0.26-0.61, p |
| doi_str_mv | 10.1371/journal.pone.0133488 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_1700480648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9b86fcdb2c684d32a93c3dc10fd1ba6d</doaj_id><sourcerecordid>1701890525</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-5fe6182dfc89b7deda33b2caec7c08401b914488fff49d1a950d2c5040b416ed3</originalsourceid><addsrcrecordid>eNptUstuEzEUHSEQLYU_QGCJDZsJfsxMPCyQQhRopKBWaVhbd-w7qaPJOLWdoP4g34XTpKVFrGzde865r5NlbxkdMDFkn1Zu63voBhvX44AyIQopn2WnrBY8rzgVzx_9T7JXIawoLYWsqpfZCa-4oLIUp9nvS--WvQvRajLHDnfQaySuJRfNCnW0O0zhkGoEJCOtnTe2X5LoyGR0NSNjbyN6CwR6Q9bzyXh6tfgbtD05xw1Ep7Hrth14Mgavbe_WQC4hWuxjIAuPENGQXzZek5nTLp_j0ro0GVlco4eNxfCZjMhsLwpx6zH_CiERfmCEfJRwt8GG19mLFrqAb47vWfbz22QxPs9nF9-n49Es1yWvYl62WDHJTatl3QwNGhCi4RpQDzWVBWVNzYq0x7Zti9owqEtquC5pQZuCVWjEWfb-oLvpXFDHEwTFhpQWklaFTIjpAWEcrNTG2zX4W-XAqruA80sFPm27Q1U3smq1SQ1UsjCCQy20MJrR1rAGqn21L8dq22aNRqeFeeieiD7N9PZaLd1OFSVnNa-SwMejgHc3WwxRrW3YXwN6dNu7vpmsacnLBP3wD_T_0xUHlPYuBI_tQzOMqr0t71lqb0t1tGWivXs8yAPp3ofiD_5w5M0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1700480648</pqid></control><display><type>article</type><title>Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Vincenzi, Bruno ; Di Maio, Massimo ; Silletta, Marianna ; D'Onofrio, Loretta ; Spoto, Chiara ; Piccirillo, Maria Carmela ; Daniele, Gennaro ; Comito, Francesca ; Maci, Eliana ; Bronte, Giuseppe ; Russo, Antonio ; Santini, Daniele ; Perrone, Francesco ; Tonini, Giuseppe</creator><creatorcontrib>Vincenzi, Bruno ; Di Maio, Massimo ; Silletta, Marianna ; D'Onofrio, Loretta ; Spoto, Chiara ; Piccirillo, Maria Carmela ; Daniele, Gennaro ; Comito, Francesca ; Maci, Eliana ; Bronte, Giuseppe ; Russo, Antonio ; Santini, Daniele ; Perrone, Francesco ; Tonini, Giuseppe</creatorcontrib><description>The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking.
To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival.
A comprehensive search of the literature was performed in electronic databases EMBASE, MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June 10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Loco-regional procedures included transarterial embolization (TAE), transarterial chemoembolization (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST was assessed using the k coefficient. For each criteria, overall survival was described in responders vs. non-responders patients, considering all target lesions response.
Among 18 initially found publications, 7 reports including 1357 patients were considered eligible. All studies were published as full-text articles. Proportion of responders according to mRECIST and EASL criteria was 62.4% and 61.3%, respectively. In the pooled population, 1286 agreements were observed between the two methods (kappa statistics 0.928, 95% confidence interval 0.912-0.944). HR for overall survival (responders versus non responders) according to mRECIST and EASL was 0.39 (95% confidence interval 0.26-0.61, p<0.0001) and 0.38 (95% confidence interval 0.24-0.61, p<0.0001), respectively.
In this literature-based meta-analysis, mRECIST and EASL criteria showed very good concordance in HCC patients undergoing loco-regional treatments. Objective response according to both criteria confirms a strong prognostic value in terms of overall survival. This prognostic value appears to be very similar between the two criteria.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0133488</identifier><identifier>PMID: 26230853</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Cancer therapies ; Carcinoma, Hepatocellular - therapy ; Clinical outcomes ; Clinical trials ; College campuses ; Conferences ; Confidence intervals ; Criteria ; Embolization ; Hepatocellular carcinoma ; Humans ; Lesions ; Liver ; Liver cancer ; Liver diseases ; Liver Neoplasms - therapy ; Medical prognosis ; Meta-analysis ; Oncology ; Patients ; Population statistics ; Prognosis ; Regional analysis ; Solid tumors ; Statistical analysis ; Statistical methods ; Studies ; Survival ; Survival Analysis ; Treatment Outcome ; Tumors</subject><ispartof>PloS one, 2015-07, Vol.10 (7), p.e0133488-e0133488</ispartof><rights>2015 Vincenzi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Vincenzi et al 2015 Vincenzi et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-5fe6182dfc89b7deda33b2caec7c08401b914488fff49d1a950d2c5040b416ed3</citedby><cites>FETCH-LOGICAL-c526t-5fe6182dfc89b7deda33b2caec7c08401b914488fff49d1a950d2c5040b416ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521926/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521926/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26230853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vincenzi, Bruno</creatorcontrib><creatorcontrib>Di Maio, Massimo</creatorcontrib><creatorcontrib>Silletta, Marianna</creatorcontrib><creatorcontrib>D'Onofrio, Loretta</creatorcontrib><creatorcontrib>Spoto, Chiara</creatorcontrib><creatorcontrib>Piccirillo, Maria Carmela</creatorcontrib><creatorcontrib>Daniele, Gennaro</creatorcontrib><creatorcontrib>Comito, Francesca</creatorcontrib><creatorcontrib>Maci, Eliana</creatorcontrib><creatorcontrib>Bronte, Giuseppe</creatorcontrib><creatorcontrib>Russo, Antonio</creatorcontrib><creatorcontrib>Santini, Daniele</creatorcontrib><creatorcontrib>Perrone, Francesco</creatorcontrib><creatorcontrib>Tonini, Giuseppe</creatorcontrib><title>Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking.
To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival.
A comprehensive search of the literature was performed in electronic databases EMBASE, MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June 10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Loco-regional procedures included transarterial embolization (TAE), transarterial chemoembolization (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST was assessed using the k coefficient. For each criteria, overall survival was described in responders vs. non-responders patients, considering all target lesions response.
Among 18 initially found publications, 7 reports including 1357 patients were considered eligible. All studies were published as full-text articles. Proportion of responders according to mRECIST and EASL criteria was 62.4% and 61.3%, respectively. In the pooled population, 1286 agreements were observed between the two methods (kappa statistics 0.928, 95% confidence interval 0.912-0.944). HR for overall survival (responders versus non responders) according to mRECIST and EASL was 0.39 (95% confidence interval 0.26-0.61, p<0.0001) and 0.38 (95% confidence interval 0.24-0.61, p<0.0001), respectively.
In this literature-based meta-analysis, mRECIST and EASL criteria showed very good concordance in HCC patients undergoing loco-regional treatments. Objective response according to both criteria confirms a strong prognostic value in terms of overall survival. This prognostic value appears to be very similar between the two criteria.</description><subject>Cancer therapies</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>College campuses</subject><subject>Conferences</subject><subject>Confidence intervals</subject><subject>Criteria</subject><subject>Embolization</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Lesions</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Liver Neoplasms - therapy</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Oncology</subject><subject>Patients</subject><subject>Population statistics</subject><subject>Prognosis</subject><subject>Regional analysis</subject><subject>Solid tumors</subject><subject>Statistical analysis</subject><subject>Statistical methods</subject><subject>Studies</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptUstuEzEUHSEQLYU_QGCJDZsJfsxMPCyQQhRopKBWaVhbd-w7qaPJOLWdoP4g34XTpKVFrGzde865r5NlbxkdMDFkn1Zu63voBhvX44AyIQopn2WnrBY8rzgVzx_9T7JXIawoLYWsqpfZCa-4oLIUp9nvS--WvQvRajLHDnfQaySuJRfNCnW0O0zhkGoEJCOtnTe2X5LoyGR0NSNjbyN6CwR6Q9bzyXh6tfgbtD05xw1Ep7Hrth14Mgavbe_WQC4hWuxjIAuPENGQXzZek5nTLp_j0ro0GVlco4eNxfCZjMhsLwpx6zH_CiERfmCEfJRwt8GG19mLFrqAb47vWfbz22QxPs9nF9-n49Es1yWvYl62WDHJTatl3QwNGhCi4RpQDzWVBWVNzYq0x7Zti9owqEtquC5pQZuCVWjEWfb-oLvpXFDHEwTFhpQWklaFTIjpAWEcrNTG2zX4W-XAqruA80sFPm27Q1U3smq1SQ1UsjCCQy20MJrR1rAGqn21L8dq22aNRqeFeeieiD7N9PZaLd1OFSVnNa-SwMejgHc3WwxRrW3YXwN6dNu7vpmsacnLBP3wD_T_0xUHlPYuBI_tQzOMqr0t71lqb0t1tGWivXs8yAPp3ofiD_5w5M0</recordid><startdate>20150731</startdate><enddate>20150731</enddate><creator>Vincenzi, Bruno</creator><creator>Di Maio, Massimo</creator><creator>Silletta, Marianna</creator><creator>D'Onofrio, Loretta</creator><creator>Spoto, Chiara</creator><creator>Piccirillo, Maria Carmela</creator><creator>Daniele, Gennaro</creator><creator>Comito, Francesca</creator><creator>Maci, Eliana</creator><creator>Bronte, Giuseppe</creator><creator>Russo, Antonio</creator><creator>Santini, Daniele</creator><creator>Perrone, Francesco</creator><creator>Tonini, Giuseppe</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150731</creationdate><title>Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis</title><author>Vincenzi, Bruno ; Di Maio, Massimo ; Silletta, Marianna ; D'Onofrio, Loretta ; Spoto, Chiara ; Piccirillo, Maria Carmela ; Daniele, Gennaro ; Comito, Francesca ; Maci, Eliana ; Bronte, Giuseppe ; Russo, Antonio ; Santini, Daniele ; Perrone, Francesco ; Tonini, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-5fe6182dfc89b7deda33b2caec7c08401b914488fff49d1a950d2c5040b416ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Cancer therapies</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>College campuses</topic><topic>Conferences</topic><topic>Confidence intervals</topic><topic>Criteria</topic><topic>Embolization</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Lesions</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Liver Neoplasms - therapy</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Oncology</topic><topic>Patients</topic><topic>Population statistics</topic><topic>Prognosis</topic><topic>Regional analysis</topic><topic>Solid tumors</topic><topic>Statistical analysis</topic><topic>Statistical methods</topic><topic>Studies</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vincenzi, Bruno</creatorcontrib><creatorcontrib>Di Maio, Massimo</creatorcontrib><creatorcontrib>Silletta, Marianna</creatorcontrib><creatorcontrib>D'Onofrio, Loretta</creatorcontrib><creatorcontrib>Spoto, Chiara</creatorcontrib><creatorcontrib>Piccirillo, Maria Carmela</creatorcontrib><creatorcontrib>Daniele, Gennaro</creatorcontrib><creatorcontrib>Comito, Francesca</creatorcontrib><creatorcontrib>Maci, Eliana</creatorcontrib><creatorcontrib>Bronte, Giuseppe</creatorcontrib><creatorcontrib>Russo, Antonio</creatorcontrib><creatorcontrib>Santini, Daniele</creatorcontrib><creatorcontrib>Perrone, Francesco</creatorcontrib><creatorcontrib>Tonini, Giuseppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vincenzi, Bruno</au><au>Di Maio, Massimo</au><au>Silletta, Marianna</au><au>D'Onofrio, Loretta</au><au>Spoto, Chiara</au><au>Piccirillo, Maria Carmela</au><au>Daniele, Gennaro</au><au>Comito, Francesca</au><au>Maci, Eliana</au><au>Bronte, Giuseppe</au><au>Russo, Antonio</au><au>Santini, Daniele</au><au>Perrone, Francesco</au><au>Tonini, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-07-31</date><risdate>2015</risdate><volume>10</volume><issue>7</issue><spage>e0133488</spage><epage>e0133488</epage><pages>e0133488-e0133488</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking.
To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival.
A comprehensive search of the literature was performed in electronic databases EMBASE, MEDLINE, COCHRANE LIBRARY, ASCO conferences and EASL conferences up to June 10, 2014. Our overall search strategy included terms for HCC, mRECIST, and EASL. Loco-regional procedures included transarterial embolization (TAE), transarterial chemoembolization (TACE) and cryoablation. Inter-method agreement between EASL and mRECIST was assessed using the k coefficient. For each criteria, overall survival was described in responders vs. non-responders patients, considering all target lesions response.
Among 18 initially found publications, 7 reports including 1357 patients were considered eligible. All studies were published as full-text articles. Proportion of responders according to mRECIST and EASL criteria was 62.4% and 61.3%, respectively. In the pooled population, 1286 agreements were observed between the two methods (kappa statistics 0.928, 95% confidence interval 0.912-0.944). HR for overall survival (responders versus non responders) according to mRECIST and EASL was 0.39 (95% confidence interval 0.26-0.61, p<0.0001) and 0.38 (95% confidence interval 0.24-0.61, p<0.0001), respectively.
In this literature-based meta-analysis, mRECIST and EASL criteria showed very good concordance in HCC patients undergoing loco-regional treatments. Objective response according to both criteria confirms a strong prognostic value in terms of overall survival. This prognostic value appears to be very similar between the two criteria.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>26230853</pmid><doi>10.1371/journal.pone.0133488</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2015-07, Vol.10 (7), p.e0133488-e0133488 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1700480648 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Cancer therapies Carcinoma, Hepatocellular - therapy Clinical outcomes Clinical trials College campuses Conferences Confidence intervals Criteria Embolization Hepatocellular carcinoma Humans Lesions Liver Liver cancer Liver diseases Liver Neoplasms - therapy Medical prognosis Meta-analysis Oncology Patients Population statistics Prognosis Regional analysis Solid tumors Statistical analysis Statistical methods Studies Survival Survival Analysis Treatment Outcome Tumors |
| title | Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T20%3A14%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Relevance%20of%20Objective%20Response%20According%20to%20EASL%20Criteria%20and%20mRECIST%20Criteria%20in%20Hepatocellular%20Carcinoma%20Patients%20Treated%20with%20Loco-Regional%20Therapies:%20A%20Literature-Based%20Meta-Analysis&rft.jtitle=PloS%20one&rft.au=Vincenzi,%20Bruno&rft.date=2015-07-31&rft.volume=10&rft.issue=7&rft.spage=e0133488&rft.epage=e0133488&rft.pages=e0133488-e0133488&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0133488&rft_dat=%3Cproquest_plos_%3E1701890525%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1700480648&rft_id=info:pmid/26230853&rft_doaj_id=oai_doaj_org_article_9b86fcdb2c684d32a93c3dc10fd1ba6d&rfr_iscdi=true |